-
Flash Briefing: IPF Patients Switching to Esbriet to Ofev Stopping Treatments, Possibly Due to Low BMI
Thanks to all of you for your feedback on our new flash briefings initiative, which will be posted every Monday and Thursday on the Pulmonary Fibrosis News homepage. We’re excited to share the second flash briefing, which can be accessed by clicking HERE.
In this briefing, our Director of Multichannel Content discusses the results from a recent study on patients with idiopathic pulmonary fibrosis (IPF) switching from Esbriet to Ofev and subsequently stopping their treatments, along with the reasons behind doing so. Unfortunately, as a patient taking Ofev for the management of my IPF, I can attest to the significant stomach/GI issues that can come from consuming this medication and how this could negatively effect folks with an already-low BMI.
Have you switched anti-fibrotic medications (Esbriet to Ofev or vice versa) since being diagnosed with IPF/PF? If so, what was the decision behind doing so?
What are your thoughts on the results of this study Michael shares, can you relate to the low BMI/weight loss issues?
Log in to reply.